PALATIN TECHNOLOGIES INC
PTN evidence brief
What we can confirm
- BioSniper Score:
- 8.7 / 10
- Market Cap:
- $21.0M
- Lead Asset:
- bremelanotide (Preclinical)
What it means
What to watch
Prepared research question
What matters most for PTN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PTN
Palatin Technologies Inc (PTN) is a biopharmaceutical company developing melanocortin receptor-targeted therapeutics, primarily MC4R agonists for rare neuroendocrine obesity disorders, with a focus on advancing a lean pipeline and leveraging strategic partnerships.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$21.0M
Cash Runway
—
Lead Asset
bremelanotide (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 1 clinical trial for PALATIN TECHNOLOGIES INC.
Palatin Technologies Inc (PTN) is a biopharmaceutical company developing melanocortin receptor-targeted therapeutics, primarily MC4R agonists for rare neuroendocrine obesity disorders, with a focus on advancing a lean pipeline and leveraging strategic partnerships.
- Palatin's strategy focuses on advancing a differentiated portfolio of melanocortin receptor-targeted therapeutics, with an emphasis on MC4R agonists for rare neuroendocrine obesity disorders [sec · filed 2026-06-25].
- As of 2026-06-30, the company reported cash & equivalents of $7.5M and shareholders' equity of $6.7M [sec].
- The company has completed Phase 2 co-administration of bremelanotide with tirzepatide for obesity, with topline results announced in March 2025 showing increased weight loss over tirzepatide alone [sec · filed 2025-06-30].
- Palatin entered into a Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim in August 2025 to develop melanocortin receptor-targeted peptides for retinal diseases [sec_mda · as of 2026-02-17].
- Based on current operating plans, the company expects existing cash to fund operations for at least twelve months following the issuance of financial statements, but will require additional financing to complete clinical trials [sec_mda · as of 2026-09-28].
What works
- Palatin has a focused pipeline on MC4R agonists for rare neuroendocrine obesity disorders, which addresses significant unmet medical need [sec · filed 2026-06-25].
- The company has established strategic partnerships, including a collaboration with Boehringer Ingelheim for retinal disease treatments [sec_mda · as of 2026-02-17].
- Positive Phase 2 results for bremelanotide co-administered with tirzepatide showed increased weight loss over tirzepatide alone [sec · filed 2025-06-30].
What to weigh
- The company has limited cash ($7.5M as of 2026-06-30) and expects to need additional financing to continue development programs [sec] [sec_mda · as of 2026-09-28].
- Substantial doubt exists about the company's ability to continue as a going concern without additional capital [sec_mda · as of 2026-09-28].
- The company's non-obesity programs (e.g., PL9643 for dry eye disease) are dependent on out-licensing or partnerships, which may not materialize [sec_mda · as of 2026-05-13].
From the filings
Quoted directly from source documents.
Company strategy focuses on MC4R agonists for rare neuroendocrine obesity disorders
“Our strategy is focused on advancing a differentiated portfolio of melanocortin receptor-targeted therapeutics, with an emphasis on MC4R agonists for rare neuroendocrine obesity disorders and other indications with significant unmet medical need.”
SEC filings · June 25, 2026
Co-administration of bremelanotide with tirzepatide showed increased weight loss
“co-administration demonstrated an increased weight loss over tirzepatide alone”
SEC filings · June 30, 2025
Substantial doubt about ability to continue as going concern
“substantial doubt exists about our ability to continue as a going concern”
SEC MD&A · September 28, 2026
Risks & what to watch (3)›
Key risks
- Cash runway uncertainty — Cash of $7.5M as of 2026-06-30 may not be sufficient to fund operations beyond twelve months; additional financing needed [sec] [sec_mda · as of 2026-09-28].
- Going concern risk — Substantial doubt exists about ability to continue as a going concern without new capital [sec_mda · as of 2026-09-28].
- Dependence on partnerships — Non-obesity programs rely on out-licensing or partnerships that may not be secured [sec_mda · as of 2026-05-13].
What to watch
- Ability to secure additional financing to extend cash runway beyond twelve months [sec_mda · as of 2026-09-28].
- Progress of MC4R agonist clinical trials planned for calendar year 2026 [sec_mda · as of 2026-02-17].
- Outcome of discussions with potential partners for non-obesity programs [sec_mda · as of 2026-05-13].
- Potential impact of economic conditions (inflation, tariffs, recession) on operations [sec_mda · as of 2026-02-17].
Sources: SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run PALATIN TECHNOLOGIES INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PALATIN TECHNOLOGIES INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.27
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
26
Total value held
$13.4M
| Holder | Shares | Value |
|---|---|---|
| driehaus capital management llc | 166,713 | $2.9M |
| janus henderson group plc | 140,000 | $2.4M |
| logos global management lp | 140,000 | $2.4M |
| ra capital management, l.p. | 70,000 | $1.2M |
| perceptive advisors llc | 61,945 | $1.1M |
| balyasny asset management l.p. | 41,169 | $717K |
| superstring capital management lp | 35,969 | $627K |
| morgan stanley | 27,272 | $475K |
| vanguard capital management llc | 18,979 | $331K |
| geode capital management, llc | 18,502 | $322K |
Showing top 10 of 26 institutional holders of PALATIN TECHNOLOGIES INC. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 8.3%
- Days to cover
- 10.5
- Shares short
- 145,791
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PTN short interestGovernance
Frequently asked questions
What is the AI investment thesis for PALATIN TECHNOLOGIES INC?
Palatin Technologies Inc (PTN) is a biopharmaceutical company developing melanocortin receptor-targeted therapeutics, primarily MC4R agonists for rare neuroendocrine obesity disorders, with a focus on advancing a lean pipeline and leveraging strategic partnerships.
What is PALATIN TECHNOLOGIES INC's lead drug candidate?
PALATIN TECHNOLOGIES INC's most advanced tracked candidate is bremelanotide (Preclinical) for Erectile Dysfunction.
Who is the CEO of PALATIN TECHNOLOGIES INC?
Dr. Carl Spana Ph.D. is the chief executive officer of PALATIN TECHNOLOGIES INC (PTN).
Where is PALATIN TECHNOLOGIES INC headquartered?
PALATIN TECHNOLOGIES INC (PTN) is headquartered in Monmouth Junction, NJ, United States.
What therapeutic areas does PALATIN TECHNOLOGIES INC focus on?
PALATIN TECHNOLOGIES INC develops therapies across Rare Disease, Immunology, Ophthalmology, Cardiovascular, Metabolic, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.